McKesson, private equity firm buy home infusion company, Option Care Health
McKesson Corporation and private equity firm Clayton Dubilier & Rice (CD&R) agreed to acquire Option Care Health, a home infusion company, for $5.8 billion. McKesson will invest $1.4 billion for a 49% stake, with CD&R taking 51%. The deal values Option Care Health at $32.05 per share, a 36% premium over Monday's closing price. Once completed, Option Care Health will become private and delist from Nasdaq.
How this was made
The 30-second read
Why it matters
The acquisition expands McKesson's reach into home‑based therapy, while Option Care shareholders receive a cash premium and the company will be delisted.
Market read
A large‑scale M&A event in the healthcare distribution space with immediate price impact on both the acquirer and target.
What to watch
Regulatory approval risk and potential antitrust scrutiny could delay or alter deal terms.
Background
McKesson partners with private‑equity firm CD&R to acquire the nation's largest independent home‑infusion provider, Option Care Health, in a $5.8 billion transaction.
Ticker impact
McKesson announced a $5.8 billion acquisition of Option Care Health, taking a 49% stake for $1.4 billion.
likely modest upside as the deal broadens McKesson's service offering and may be viewed as strategic growth.
The acquisition is a large‑scale, first‑report M&A event; investors typically reward strategic expansion.
Option Care Health will be taken private and its Nasdaq listing will be cancelled after the $5.8 billion deal closes.
significant downward pressure as the market prices in the buyout premium and delisting.
Buyout announcements with a premium above market price typically trigger a rapid decline in the target's share price.
Market effects
The deal underscores consolidation in the home infusion and broader drug‑distribution sector, pressuring peers to consider similar strategic moves.
U.S. healthcare services market may see increased M&A activity as large distributors expand into patient‑level care.
Limited to U.S. healthcare and distribution firms; no immediate global macro effect.
Counterpoint
The premium paid may be excessive if integration costs rise, potentially weighing on McKesson's earnings in the near term.
Key entities
- CompanyMcKesson Corporation
U.S. drug wholesaler and distributor.
- CompanyOption Care Health
Largest independent home‑infusion provider, formerly listed on Nasdaq.
- Private EquityClayton Dubilier & Rice
Private‑equity firm taking a 51% stake in the deal.
